JP2542792C - - Google Patents
Info
- Publication number
- JP2542792C JP2542792C JP2542792C JP 2542792 C JP2542792 C JP 2542792C JP 2542792 C JP2542792 C JP 2542792C
- Authority
- JP
- Japan
- Prior art keywords
- reservoir
- user
- patient
- medicament
- reservoirs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 claims description 78
- 239000002550 vasoactive agent Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 18
- 210000003491 Skin Anatomy 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 13
- 239000003589 local anesthetic agent Substances 0.000 claims description 12
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000969 carrier Substances 0.000 claims description 10
- 210000004400 Mucous Membrane Anatomy 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000003792 electrolyte Substances 0.000 claims description 6
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 5
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 150000002500 ions Chemical class 0.000 claims description 4
- 229960004194 lidocaine Drugs 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 3
- 230000004059 degradation Effects 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 229940079593 drugs Drugs 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 13
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive Effects 0.000 description 5
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- VSHFRHVKMYGBJL-CKUXDGONSA-N (S)-ropivacaine hydrochloride hydrate Chemical compound O.[Cl-].CCC[NH+]1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C VSHFRHVKMYGBJL-CKUXDGONSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- -1 for example Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002227 vasoactive Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229960004393 Lidocaine Hydrochloride Drugs 0.000 description 2
- 229960003691 ROPIVACAINE HYDROCHLORIDE MONOHYDRATE Drugs 0.000 description 2
- 230000003213 activating Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000000887 hydrating Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000000188 Diaphragm Anatomy 0.000 description 1
- SFKQVVDKFKYTNA-DZCXQCEKSA-N Felypressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](N)CSSC1 SFKQVVDKFKYTNA-DZCXQCEKSA-N 0.000 description 1
- 229960001527 Felypressin Drugs 0.000 description 1
- 108010045937 Felypressin Proteins 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229940053973 Novocaine Drugs 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001813 Ropivacaine hydrochloride Drugs 0.000 description 1
- 241000785686 Sander Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 238000007374 clinical diagnostic method Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 201000008125 pain agnosia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2542792B2 (ja) | ユ―ザ作動型のイオン導入式装置 | |
| EP0934098B1 (en) | User activated iontophoretic device and method for activating same | |
| US5797867A (en) | Iontophoretic drug delivery system, including method for activating same for attachment to patient | |
| JP4154017B2 (ja) | イオントフォレーシス装置および薬物ユニット | |
| KR100601776B1 (ko) | 전해질 경피 전달 장치를 위한 무수 약물 저장기 | |
| JPH03151982A (ja) | タンパク及びペプチド性薬物の経皮投与器具 | |
| JPH11239621A (ja) | イオントフォレーシス装置 | |
| BRPI0616771A2 (pt) | dispositivo de iontoforese para liberar múltiplos agentes ativos para interfaces biológicas | |
| BRPI0616487A2 (pt) | aparato e método de iontoforese para liberação sistêmica de agentes ativos | |
| JP4033382B2 (ja) | インスリン投与装置 | |
| EP0934097B1 (en) | Iontophoretic drug delivery system, including method for activating same | |
| WO2005063331A1 (ja) | 用時活性化型イオントフォレーシスデバイス | |
| EP0586666B2 (en) | User activated iontophoretic device | |
| EP0411146A1 (en) | Interface for iontophoresis | |
| JP4154016B2 (ja) | イオントフォレーシス装置およびその組み立て方法 | |
| JP2542792C (ko) | ||
| JP2818771B2 (ja) | イオントフォレーシス用インターフェイス | |
| JPH02234774A (ja) | イオントフォレーゼ用インタフェース | |
| JP3119488B2 (ja) | 水溶性ステロイド用イオントフォレーシスデバイス | |
| JP2798272B2 (ja) | イオントフォレーゼ用インタフェース |